PmcKwd.i
Checkpoint
Pmc
Racine
Checkpoint
Pmc
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Pmc)

Index « PmcKwd.i » - entrée « Tocilizumab »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Tnf-alpha < Tocilizumab < Tofacitinib  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 43.
[0-20] [0 - 20][0 - 43][20-40]**** probable Xml problem ****
Ident.Authors (with country if any)Title
000002 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000028 (2020) Masaki Shimizu [Japon] ; Mao Mizuta [Japon] ; Nami Okamoto [Japon] ; Takahiro Yasumi [Japon] ; Naomi Iwata [Japon] ; Hiroaki Umebayashi [Japon] ; Yuka Okura [Japon] ; Noriko Kinjo [Japon] ; Tomohiro Kubota [Japon] ; Yasuo Nakagishi [Japon] ; Kenichi Nishimura [Japon] ; Mariko Mohri [Japon] ; Masato Yashiro [Japon] ; Junko Yasumura [Japon] ; Hiroyuki Wakiguchi [Japon] ; Masaaki Mori [Japon]Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
000048 (2020) Chi Zhang [République populaire de Chine] ; Zhao Wu [République populaire de Chine] ; Jia-Wen Li [République populaire de Chine] ; Hong Zhao [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
000063 (2020) Charlotte Borocco [France] ; Claire Ballot-Schmit [France] ; Oanez Ackermann [France] ; Nathalie Aladjidi [France] ; Jeremie Delaleu [France] ; Vannina Giacobbi-Milet [France] ; Sarah Jannier [France] ; Eric Jeziorski [France] ; François Maurier [France] ; Yves Perel [France] ; Christophe Piguet [France] ; Eric Oksenhendler [France] ; Isabelle Koné-Paut [France] ; Caroline Galeotti [France]The French paediatric cohort of Castleman disease: a retrospective report of 23 patients
000075 (2020) Gali Epstein Shochet [Israël] ; Elizabetha Brook [Israël] ; Becky Bardenstein-Wald [Israël] ; David Shitrit [Israël]TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
000084 (2020) Chayma Ladhari [France] ; Pierre Le Blay [France] ; Thierry Vincent [France] ; Ahmed Larbi [France] ; Emma Rubenstein [France] ; Rosanna Ferreira Lopez [France] ; Christian Jorgensen [France] ; Yves-Marie Pers [France]Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
000092 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000107 (2020) Giuseppe MagroSARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
000122 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000142 (2020) Chih-Chia Lu [République populaire de Chine] ; Mei-Yu Chen [République populaire de Chine] ; Yuh-Lih ChangPotential therapeutic agents against COVID-19: What we know so far
000238 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000239 (2020) Etienne Dufranc [France] ; Arnaud Del Bello [France] ; Julie Belliere [France] ; Nassim Kamar [France] ; Stanislas Faguer [France]IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
000272 (2020) S. P. Mollan [Royaume-Uni] ; K. Paemeleire [Belgique] ; J. Versijpt [Belgique] ; R. Luqmani ; A. J. Sinclair [Royaume-Uni]European Headache Federation recommendations for neurologists managing giant cell arteritis
000305 (2020) Ming Zhao [République populaire de Chine]Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
000340 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Jinglan Pei [États-Unis]Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
000367 (2020) Bingwen Liu [République populaire de Chine] ; Min Li [République populaire de Chine] ; Zhiguang Zhou [République populaire de Chine] ; Xuan Guan [États-Unis] ; Yufei Xiang [République populaire de Chine]Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
000416 (2020) Franco Maria Buonaguro [Italie] ; Igor Puzanov [États-Unis] ; Paolo Antonio Ascierto [Italie]Anti-IL6R role in treatment of COVID-19-related ARDS
000440 (2020) Haneul Kim [Corée du Sud] ; Seungye Baek [Corée du Sud] ; Seung-Min Hong [Corée du Sud] ; Jaeseon Lee [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Jennifer Lee [Corée du Sud] ; Mi-La Cho [Corée du Sud] ; Seung-Ki Kwok [Corée du Sud] ; Sung-Hwan Park [Corée du Sud]1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis
000458